Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Chang David D					2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ ALLO ]								5. Relationship of Report (Check all applicable) X Director			ing Person(s) to Issuer 10% Owner			
(Last) (First) (Middle) 210 EAST GRAND AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 03/26/2021								X Officer (give title below) Other (specify below)  President and CEO							
(Street) SOUTH FRANCI	( ' /	Δ 9	4080		4. If Amendment, Date of 03/30/2021				of Original Filed (Month/Day/Year)								up Filing (Check Appl ne Reporting Person ore than One Reporti		
(City)	(St	ate) (Z	Zip)																
		Table	I - No	n-Deriva	tive S	Secui	rities	Acc	quired	l, Dis	sposed of	, or E	Benefi	icial	ly Own	ed			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				nnd Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) (D)	Pric	e:e	Reported Transact (Instr. 3	ction(s)			(Instr. 4)		
Common	Common Stock													2,28	4,869		D		
Common Stock														1,201,108				See footnote <sup>(1)</sup>	
Common Stock 08/31/			08/31/20	020				G <sup>(2)</sup>		205,778	A	\$0	.00	856,044				See footnote <sup>(3)</sup>	
Common Stock 08/31/2			08/31/20	020				G <sup>(4)</sup>		205,778	A	\$0	.00	856,044				See footnote <sup>(5)</sup>	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)  2. Conversion Date (Month/Day/Year) Price of Derivative Security		Execu if any	any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S (I	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares	er					
1. Securities		ses: ne of the Chang 2006									,	_	-			_			

- 2. On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary.
- 3. Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- 4. On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary.
- 5. Securities held in the name of the RTC 2019 Trust dated October 1, 2019.

## Remarks:

/s/ Veer Bhavnagri, Attorney-

04/02/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.